Daicel Corporation
4202・Prime Market・Chemicals
Medical & Healthcare
A healthcare-focused segment centered on chiral separation columns (chiral columns) and health food ingredients
| Period | Current | Previous | Change |
|---|---|---|---|
| Net sales (full year) | ¥16,227 million | ¥14,438 million | ↑ |
| Operating income (full year) | ¥427 million | ¥261 million | ↑ |
| Segment assets | ¥16,056 million | ¥15,427 million | ↑ |
| Depreciation and amortization | ¥985 million | ¥1,015 million | ↓ |
| Increase in property, plant and equipment and intangible assets (capital expenditures) | ¥1,289 million | ¥880 million | ↑ |
Business Details
Comprises two businesses: Life Science (chiral columns and analytical services) and Healthcare (health food ingredients and cosmetics ingredients). Chiral Technologies, Inc. (U.S.), Chiral Technologies Europe S.A.S. (Europe), Daicel Chiral Technologies (China) Co., Ltd. and others sell chiral separation columns globally and provide technical services. Health food ingredients benefit from strong sales of customers' supplement products. Although small, accounting for approximately 2.8% of consolidated Group net sales, the segment is positioned as a high-value-added growth area.
Recent Overview
Achieved higher revenue and profit driven by increased chiral column sales volume and strong health food ingredient sales
In FY2026 (ending March 2026), the segment achieved significant increases in both revenue and profit, with net sales of ¥16,227 million (up 12.4% year on year) and operating income of ¥427 million (up 63.6% year on year). In the Life Science business, increased sales volume of chiral columns contributed to the results, while in the Healthcare business, sales volume of health food ingredients increased on the back of strong sales of customers' supplement products. Capital expenditures also increased 46.5% year on year to ¥1,289 million, maintaining an aggressive investment stance.
Key Products
Growth Drivers
- Increased sales volume of chiral columns (contributed to a 12.4% year-on-year increase in revenue in FY2026)
- Expanding demand for health food ingredients driven by strong sales of customers' supplement products in the Healthcare business
- Solid demand for health food ingredients (1,3-Butylene Glycol, etc.) in the cosmetics market
- Business development in emerging markets, including expansion of analytical services in India
- Development of medical-related businesses such as DDS (drug delivery systems) and medical materials based on the medium-term strategy
Risks
- Fluctuations in profit margin due to differences in product sales mix (operating margin remains at a low level)
- Risk of declining sales of packing materials for chiral columns
- Profit pressure from increased expenses accompanying higher sales volume (cost management is a challenge amid scale expansion)
- Small scale, accounting for approximately 2.8% of consolidated Group net sales, limiting the segment's contribution to profits
- History of impairment losses on business assets in the past, creating a latent risk of asset value impairment
Last updated: June 17, 2026